Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production

Pharmacology

Volumn 81, Issue 4, 2008, Pages 317-324

  Kim, Hyun Sun ^a   Oh, Jin Mi ^a   Jin, Dong Hoon ^b   Yang, Kyu Hwan ^c   Moon, Eun Yi ^a  

^a Sejong University   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

Hypoxia inducible factor 1; Paclitaxel; Reactive oxygen species; Vascular endothelial growth factor

Indexed keywords

ACETYLCYSTEINE; DIPHENYLIODONIUM SALT; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PACLITAXEL; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; METASTASIS; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; HYDROGEN PEROXIDE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; NF-KAPPA B; PACLITAXEL; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43449120679     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119756     Document Type: Article

References (31)

1. Horwitz SB: Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5(suppl 6):S3-S6.
2. Martin V: Overview of paclitaxel (Taxol). Semin Oncol Nurs 1993;9:2-5.
3. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG: Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-662.
4. Fawcett H, Mader JS, Robichaud M, Giacomantonio C, Hoskin DW: Contribution of reactive oxygen species and caspase-3 to apoptosis and attenuated ICAM-1 expression by paclitaxel-treated MDA-MB-435 breast carcinoma cells. Int J Oncol 2005;27:1717-1726.
5. Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, Fang J, Jiang BH: Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006;41:1521-1533.
6. Richard DE, Berra E, Pouyssegur J: Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266:718-722.
7. Semenza GL: HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000;19:59-65.
8. Gao N, Shen L, Zhang Z, Leonard SS, He H, Zhang XG, Shi X, Jiang BH: Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem 2004;255:33-45.
9. Ido Y, Chang KC, Lejeune WS, Bjercke RJ, Reiser KM, Williamson JR, Tilton RG: Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 2001;8:251-263.
10. 12 skeletal myotubes through a PI3K/Akt pathway. Am J Physiol Lung Cell Mol Physiol 2001;280:L585-L592.
11. Zhou Q, Liu LZ, Fu B, Hu X, Shi X, Fang J, Jiang BH: Reactive oxygen species regulate insulin-induced VEGF and HIF-1α expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007;28:28-37.
12. Maulik N, Das DK: Redox signaling in vascular angiogenesis. Free Radic Biol Med 2002;33:1047-1060.
13. Michiels C, Minet E, Mottet D, Raes M: Regulation of gene expression by oxygen: NF-κB and HIF-1, two extremes. Free Radic Biol Med 2002;33:1231-1242.
14. Schreck R, Albermann K, Baeuerle PA: Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992;17:221-237.
15. Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
16. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: Microtubule disruption utilizes an NF κB-dependent pathway to stabilize HIF-1α protein. J Biol Chem 2003;278:7445-7452.
17. Celletti FL, Waugh JM, Amabile PG, Kao EY, Boroumand S, Dake MD: Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol 2002;13:703-707.
18. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6:4874-4884.
19. Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D: Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98:1377-1385.
20. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31-36.
21. Xu G, Pan J, Martin C, Yeung SC: Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2001;86:1769-1777.
22. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271-277.
23. Jeon YJ, Kim YK, Lee M, Park SM, Han SB, Kim HM: Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-κB/Rel in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 2000;294:548-554.
24. Pierce JW, Lenardo M, Baltimore D: Oligonucleotide that binds nuclear factor NF-κB acts as a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci USA 1988;85:1482-1486.
25. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J, Choi S, Jung CR, Im DS: Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004;10:938-949.
26. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Lee MH, Jin SM, Jin GY, Yoo WH, Lee YC: Hydrogen peroxide induces vascular permeability via regulation of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2006;35:190-197.
27. Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265.
28. Moon EY, Han YH, Lee DS, Han YM, Yu DY: Reactive oxygen species induced by the deletion of peroxiredoxin II (PrxII) increases the number of thymocytes resulting in the enlargement of PrxII-null thymus. Eur J Immunol 2004;34:2119-2128.
29. Lee M, Koh WS, Han SS: Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett 2003;193:57-64.
30. Niu M, Nachmias VT: Increased resistance to apoptosis in cells overexpressing thymosin β4: a role for focal adhesion kinase pp125FAK. Cell Adhes Commun 2000;7:311-320.
31. Oh SY, Song JH, Gil JE, Kim JH, Yeom YI, Moon EY: ERK activation by thymosin-β-4 (TB4) overexpression induces paclitaxel-resistance. Exp Cell Res 2006;312:1651-1657.